Nocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis.
Nocardia
Pneumocystis jirovecii
bacteria
drug allergy
fungi
immunocompromised
respiratory infections
sulfa
trimethoprim/sulfamethoxazole
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
entrez:
21
9
2021
pubmed:
22
9
2021
medline:
8
10
2021
Statut:
ppublish
Résumé
Prophylactic trimethoprim/sulfamethoxazole (TMP/SMX) prevents Pneumocystis jirovecii pneumonia and nocardiosis in immunocompromised patients but sometimes is avoided because of purported allergies or side effects. Of 25 immunocompromised patients receiving alternative prophylaxis in whom nocardiosis developed, 16 subsequently tolerated TMP/SMX treatment. Clinicians should consider TMP/SMX allergy evaluation and rechallenging to assess patient tolerance.
Identifiants
pubmed: 34545802
doi: 10.3201/eid2710.210620
pmc: PMC8462344
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2734-2736Références
Am J Transplant. 2018 Feb;18(2):462-466
pubmed: 28898546
Rev Infect Dis. 1982 Mar-Apr;4(2):315-25
pubmed: 6981158
J Lab Clin Med. 2005 Mar;145(3):156-62
pubmed: 15871308
Transpl Infect Dis. 2018 Aug;20(4):e12902
pubmed: 29668123
Cochrane Database Syst Rev. 2014 Oct 01;(10):CD005590
pubmed: 25269391
Clin Infect Dis. 2016 Aug 1;63(3):338-45
pubmed: 27090987
Transpl Infect Dis. 2016 Apr;18(2):169-75
pubmed: 26809666
Clin Infect Dis. 2018 Oct 30;67(10):1637-1639
pubmed: 29771330